The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials.
Conclusions: DC-CIK therapy can simultaneously improve the antitumor immunity and tumor responses. DC-CIK therapy, especially DC-CIK cells, can improve antitumor immunity through increasing the T lymphocyte subsets, CIK cell, and NK cells in peripheral blood. The one cycle to two cycles may be optimal cycle, and the NP or GP may be optimal combination.
PMID: 30648123 [PubMed - in process]
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | China Health | Clinical Trials | Databases & Libraries | Lung Cancer | Non-Small Cell Lung Cancer | Statistics | Study